相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Whole transcriptome sequencing reveals recurrent NOTCH1 mutations in mantle cell lymphoma
Robert Kridel et al.
BLOOD (2012)
IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma
Rob A. Cairns et al.
BLOOD (2012)
Making Personalized Cancer Medicine a Reality: Challenges and Opportunities in the Development of Biomarkers and Companion Diagnostics
David R. Parkinson et al.
CLINICAL CANCER RESEARCH (2012)
Analytical Performance of a Real-time PCR-based Assay for V600 Mutations in the BRAF Gene, Used as the Companion Diagnostic Test for the Novel BRAF Inhibitor Vemurafenib in Metastatic Melanoma
Harkanwal Halait et al.
DIAGNOSTIC MOLECULAR PATHOLOGY (2012)
Translating cancer 'omics' to improved outcomes
Emily A. Vucic et al.
GENOME RESEARCH (2012)
Adaptive Clinical Trials A Partial Remedy for the Therapeutic Misconception?
William J. Meurer et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2012)
Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study
Barbara Pro et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma
Anas Younes et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Microarray Gene Expression Analysis of Fixed Archival Tissue Permits Molecular Classification and Identification of Potential Therapeutic Targets in Diffuse Large B-Cell Lymphoma
Kim Linton et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2012)
Prepping Omics for the Clinic
Rabiya S. Tuma
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2012)
Predictive Biomarkers in Advance of a Companion Drug: Ahead of Their Time?
Robin K. Kelley et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2012)
New report sets guidelines for omics research
Norra MacReady
LANCET ONCOLOGY (2012)
Oxford Nanopore announcement sets sequencing sector abuzz
Michael Eisenstein
NATURE BIOTECHNOLOGY (2012)
The road to resistance: EGFR mutation and cetuximab
Alberto Bardelli et al.
NATURE MEDICINE (2012)
Adaptive clinical trials in oncology
Donald A. Berry
NATURE REVIEWS CLINICAL ONCOLOGY (2012)
Role of randomized phase III trials in an era of effective targeted therapies
Manish R. Sharma et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2012)
Oncology trials-the elephant in the room
Rebecca Kirk et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2012)
Brentuximab vedotin
Anas Younes et al.
NATURE REVIEWS DRUG DISCOVERY (2012)
Immunohistochemical Detection of MYC-driven Diffuse Large B-Cell Lymphomas
Michael J. Kluk et al.
PLOS ONE (2012)
Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27)
Michael T. McCabe et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing
Jens G. Lohr et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
New paradigms in translational science research in cancer biomarkers
Paul D. Wagner et al.
TRANSLATIONAL RESEARCH (2012)
Cancer biomarkers, companion diagnostics and personalized oncology FOREWORD
Jeffrey S. Ross
BIOMARKERS IN MEDICINE (2011)
Prognostic significance of immunohistochemical biomarkers in diffuse large B-cell lymphoma: a study from the Lunenburg Lymphoma Biomarker Consortium
Gilles Salles et al.
BLOOD (2011)
Cancer Biomarkers: Closer to Delivering on their Promise
Lance A. Liotta et al.
CANCER CELL (2011)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
BCL2 Predicts Survival in Germinal Center B-cell-like Diffuse Large B-cell Lymphoma Treated with CHOP-like Therapy and Rituximab
Javeed Iqbal et al.
CLINICAL CANCER RESEARCH (2011)
New Strategies in Diffuse Large B-cell Lymphoma: Translating Findings from Gene Expression Analyses into Clinical Practice
Jonathan W. Friedberg
CLINICAL CANCER RESEARCH (2011)
Adaptive Clinical Trials: The Promise and the Caution
Donald A. Berry
JOURNAL OF CLINICAL ONCOLOGY (2011)
Crizotinib and Testing for ALK
Alice T. Shaw et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2011)
Quantitative image analysis in the assessment of diffuse large B-cell lymphoma
Devon S. Chabot-Richards et al.
MODERN PATHOLOGY (2011)
Erlotinib, gefitinib, or chemotherapy for EGFR mutation-positive lung cancer?
Tetsuya Mitsudomi
LANCET ONCOLOGY (2011)
Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trial
Anas Younes et al.
LANCET ONCOLOGY (2011)
A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma
T. E. Witzig et al.
LEUKEMIA (2011)
Oncogenically active MYD88 mutations in human lymphoma
Vu N. Ngo et al.
NATURE (2011)
Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma
Ryan D. Morin et al.
NATURE (2011)
Analysis of the coding genome of diffuse large B-cell lymphoma
Laura Pasqualucci et al.
NATURE GENETICS (2011)
Cancer genomics: from discovery science to personalized medicine
Lynda Chin et al.
NATURE MEDICINE (2011)
Beyond chemotherapy: new agents for targeted treatment of lymphoma
Anas Younes
NATURE REVIEWS CLINICAL ONCOLOGY (2011)
TRIAL WATCH Phase III and submission failures: 2007-2010
John Arrowsmith
NATURE REVIEWS DRUG DISCOVERY (2011)
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
Paul B. Chapman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Everolimus for Advanced Pancreatic Neuroendocrine Tumors.
James C. Yao et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Utility of mTOR Inhibition in Hematologic Malignancies
Anas Younes et al.
ONCOLOGIST (2011)
The clinicopathological analysis of 303 cases with malignant lymphoma classified according to the World Health Organization classification system in a single institute of Taiwan
Wei-Liang Chen et al.
ANNALS OF HEMATOLOGY (2010)
Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia
Jonathan W. Friedberg et al.
BLOOD (2010)
An Overview of the Optimal Planning, Design, and Conduct of Phase I Studies of New Therapeutics
Patricia M. LoRusso et al.
CLINICAL CANCER RESEARCH (2010)
Association of KRAS p.G13D Mutation With Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With Cetuximab
Wendy De Roock et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2010)
Safety, Pharmacokinetics, and Preliminary Clinical Activity of Inotuzumab Ozogamicin, a Novel Immunoconjugate for the Treatment of B-Cell Non-Hodgkin's Lymphoma: Results of a Phase I Study
Anjali Advani et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial
Kathy S. Albain et al.
LANCET ONCOLOGY (2010)
Gene-expression-based prognostic assays for breast cancer
Chungyeul Kim et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2010)
Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas.
Anas Younes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Anaplastic Lymphoma Kinase Inhibition in Non-Small-Cell Lung Cancer
Eunice L. Kwak et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Pathway-Based Identification of Biomarkers for Targeted Therapeutics: Personalized Oncology with PI3K Pathway Inhibitors
Jannik N. Andersen et al.
SCIENCE TRANSLATIONAL MEDICINE (2010)
A Phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma
Andres Forero-Torres et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
I-SPY 2: An Adaptive Breast Cancer Trial Design in the Setting of Neoadjuvant Chemotherapy
A. D. Barker et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2009)
Phase I Study of the Humanized Anti-CD40 Monoclonal Antibody Dacetuzumab in Refractory or Recurrent Non-Hodgkin's Lymphoma
Ranjana Advani et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Phase III Study to Evaluate Temsirolimus Compared With Investigator's Choice Therapy for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
Georg Hess et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Targeting the phosphoinositide 3-kinase pathway in cancer
Pixu Liu et al.
NATURE REVIEWS DRUG DISCOVERY (2009)
A practical approach to the understanding and diagnosis of lymphoma: an assessment of the WHO classification based on immunoarchitecture and immuno-ontogenic principles
Leonard Hwan Cheong Tan
PATHOLOGY (2009)
Novel treatment strategies for patients with relapsed classical Hodgkin lymphoma
A. Younes
Hematology-American Society of Hematology Education Program (2009)
Classification of Non-Hodgkin's Lymphoma
David J. Good et al.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2008)
Activity of single agent temsirolimus (CCI-779) in non-mantle cell non-Hodgkin lymphoma subtypes
S. M. Smith et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Efficacy of everolimus in advanced renal cell carcinoma:: a double-blind, randomised, placebo-controlled phase III trial
Robert J. Motzer et al.
LANCET (2008)
A phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignancies
Nancy L. Bartlett et al.
BLOOD (2008)
Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity
Lao H. Saal et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma
Michael J. Robertson et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Plasma cytokine and soluble receptor signature predicts outcome of patients with classical Hodgkin's lymphoma:: A study from the Groupe d'Etude des Lymphomes de l'Adulte
Rene-Olivier Casasnovas et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: Validation of tissue microarray as a prerequisite for broad clinical applications - A study from the Lunenburg Lymphoma Biomarker Consortium
Daphne de Jong et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting
John C. Sok et al.
CLINICAL CANCER RESEARCH (2006)
KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer
A Lièvre et al.
CANCER RESEARCH (2006)
BCL2 expression is a prognostic marker for the activated B-cell-like type of diffuse large B-cell lymphoma
J Iqbal et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Randomised phase III study of R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by high-dose therapy and a second randomisation to maintenance treatment with rituximab or not: an update of the CORAL study
H Hagberg et al.
ANNALS OF ONCOLOGY (2006)
Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma
TE Witzig et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
REporting recommendations for tumor MARKer prognostic studies (REMARK)
LM McShane et al.
NATURE CLINICAL PRACTICE GASTROENTEROLOGY & HEPATOLOGY (2005)
REporting recommendations for tumor MARKer prognostic studies (REMARK)
LM McShane et al.
NATURE CLINICAL PRACTICE ONCOLOGY (2005)
REporting recommendations for tumor MARKer prognostic studies (REMARK)
LM McShane et al.
NATURE CLINICAL PRACTICE UROLOGY (2005)
Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: Phase I/II clinical trial results
JP Leonard et al.
CLINICAL CANCER RESEARCH (2004)
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer
S Paik et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray
CP Hans et al.
BLOOD (2004)
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
TJ Lynch et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Molecular diagnosis of the hematologic cancers
LM Staudt
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Gene expression profiling predicts clinical outcome of breast cancer
LJ van't Veer et al.
NATURE (2002)
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
AA Alizadeh et al.
NATURE (2000)
分享论文
